MGC Pharmaceuticals Limited ("MGC") (MXC: LSE, ASX) is a next-generation Pharma licensed company at the forefront of the emerging global plant-inspired pharmaceutical market. With central offices in the United Kingdom, Production centres in Slovenia and Malta and Research centres in Slovenia and Israel MGC is leading the market in research, production and sales of its pharmaceutical products. MGC has developed an efficient production pipeline of plant-inspired medications, led by three products currently available to patients, with other products in clinical development and testing. All of MGC’s products are produced under the strict rule of EUGMP guidelines and MGC holds one of the few facilities to be approved for compounding plant-inspired medications globally. Which has three clinical arms: a. Neurology b. Oncology c. Autoimmune MGC Pharma’s goal is to provide “Cost Effective, Standardized, Affordable Medicines”. This goal is cemented by MGC Pharma having established a full EU-GMP certified facility in Slovenia and Malta. It is one of the few companies in the world that has manufactured standardized API of plant-inspired medicines and has formulated those into effective, consistent, plant-inspired medicines. MGC Pharma's three flagship products, CannEpil™, CogniCann™, and Cimetra™, are in the late stage of clinical development and are the first in MGC Pharma’s pipeline, with further products such as IrniCann (Glioblastoma), InCann (Crohn’s disease and colitis), and TopiCann (anti-inflammatory) following close behind.